<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803673</url>
  </required_header>
  <id_info>
    <org_study_id>110106</org_study_id>
    <nct_id>NCT00803673</nct_id>
  </id_info>
  <brief_title>A Healthy Volunteer Study With Inhaled GSK573719 and Placebo</brief_title>
  <official_title>A Single Centre, Randomized, Double-blind, Dose Ascending, Placebo-controlled Study, in Two Parts, to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Inhaled Doses of GSK573719 and Placebo Formulated With the Excipient Magnesium Stearate, in Healthy Subjects and in a Healthy Population of Cytochrome P450 Isoenzyme 2D6 Poor Metabolisers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to look at a new formulation of GSK573719 to see if it is safe and tolerated in
      healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2008</start_date>
  <completion_date type="Actual">October 16, 2008</completion_date>
  <primary_completion_date type="Actual">October 16, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General safety and tolerability endpoints: Adverse Events (AE), HR, BP, 12- lead ECG and lung function (FEV1) and clinical laboratory safety tests</measure>
    <time_frame>Various</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood and urine levels of study drug</measure>
    <time_frame>various</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mcg 719</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mcg '719</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mcg '719</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo '719</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mcg</intervention_name>
    <description>100mcg '719</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500mcg</intervention_name>
    <description>500mcg '719</description>
    <arm_group_label>Active 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mcg</intervention_name>
    <description>1000mcg '719</description>
    <arm_group_label>Active 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo '719</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy.

          -  Male or female 18 to 65 years of age inclusive.

          -  Non-childbearing women or women of child bearing potential who agree to use
             contraception

          -  Subject has had their CYP2D6 genotype confirmed and can be included in either of the
             following parts:

          -  Part 1: may include extensive, intermediate and ultra-rapid metabolizers

          -  Part 2: includes only poor (no enzyme activity) metabolizers, with previously
             confirmed phenotype

          -  Body Mass Index within the range 18 - 30 kg/m2 (inclusive).

          -  Capable of giving written informed consent

          -  Normal ECG;

          -  Normal lung function.

          -  Non-smokers (never smoked or not smoking for &gt;6 months with &lt;10 pack years history
             (Pack years = (cigarettes per day smoked/20) x number of years smoked))

          -  A signed and dated written informed consent is obtained from the subject

          -  The subject is capable of giving informed consent

          -  Available to complete the study

        Exclusion Criteria:

          -  Any clinically important abnormality identified at the screening medical assessment
             (physical examination/medical history), clinical laboratory tests, or ECG (12-lead).
             24hr Holter monitoring outside normal limits.

          -  A history of breathing problems (i.e. history of asthmatic symptomatology).

          -  Abnormal ECG.

          -  Abnormal blood pressure.

          -  Abnormal heart rate

          -  The subject has a positive pre-study drug/alcohol screen.

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within three months of screening.

          -  A positive test for HIV antibody (if determined by the local SOPs).

          -  History of high alcohol consumption within three months of the study

          -  The subject has participated in a clinical trial and has received an IP within the
             following time period prior to the first dosing day in the current study: 30 days,
             five half-lives or twice the duration of the biological effect of the IP (whichever is
             longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Use of prescription or non-prescription drugs, (except for simple analgesics e.g.
             paracetamol), including vitamins, herbal and dietary supplements (including St John's
             Wort) within seven days (or 14 days if the drug is a potential enzyme inducer) or five
             half-lives (whichever is longer) prior to the first dose of study medication

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500mL within a 56 day period.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or
             nicotine-containing products prior to screening.

          -  The subject is unable to use the novel dry powder inhaler correctly.

          -  The subject has a known allergy or hypersensitivity to milk protein or the excipients
             magnesium stearate and lactose monohydrate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/110106?search=study&amp;search_terms=110106#rs</url>
    <description>Results for study 110106 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>New formulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110106</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110106</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110106</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110106</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110106</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110106</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110106</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

